![EP 60: The Year 2021 in Review with Dr Sukh Nijjer – Part 1| recent cardiology trials](https://assets.radcliffecardiology.com/s3fs-public/podcast/2024-03/EP_60.png?VersionId=x8pIMdjzIO6UUET8mGUAqfsZqj.8weon)
In the last Parallax episode of the year,Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.
This year we had a number of studies that helped clarify our understanding of the world of antiplatelets: First, Ankur and Sukh discuss the take-home messages from HOST-EXAM, a Korean study presented at ACC 2021. They discuss their clinical experiences within the UK and US setting. Next, Sukh talks about the STOPDAPT-2 ACS study, presented at ESC 2021. Sukh interprets the findings in the light of TWILIGHTand summarises his thoughts on the therapy.
2021 was not a great year for physiology: Sukh shares his take on FLOWER-MI, presented at ACC 2021. He offers a deep dive into the data and highlights both the importance of the findings and the limitations of the study.
Next, they discuss RIPCORD 2 from ESC 2021 and finally, Sukh highlights the findings from the FAME 3 trial.
What is the importance of genotype testing in the world of antiplatelets? What are the considerations for clinicians? Should we stop using FFR? How can we incorporate novel findings to patient care? What are the practical considerations that we should take into account when looking at the physiology trials of 2021?
Stay tuned for Part 2 - heart failure and surgical trials coming in 2022.
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
![Edwards: www.edwardstavr.com](https://assets.radcliffecardiology.com/article/2024-03/edwards_logo_v2_423_rgb_pos_jpg_3.jpg?VersionId=wvCe3eONeAb99zHg.28xvhD2n6mr2qy_)
Brought to you by Edwards: www.edwardstavr.com
![EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/1920x1080_PP_EP61.png?VersionId=GBUOTD1Now0KlMBv1ZqsaenpUrh7dUtk&itok=ZyO2ze7u)
![Drug-Coated Balloons Small-Vessel CAD Brilakis - Megaly](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Brilakis-and-Megaly.png?VersionId=5e3JcL291o0RS5trUH3gXO6gawEByNsF&itok=wne5Gva2)
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
![04: J Dawn Abbott On Recent Developments In Percutaneous Coronary Intervention](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-J-Dawn-Abbot.png?VersionId=or7p.TA7ztGjeOTgC8mLKMLM0BtmWa0.&itok=b5t4ZU5g)
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
![03: Athena Poppas On Effective Management Of Hypertension](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Athena-%20Poppas_2.png?VersionId=h4WiM05z59aZvdzCLsJoSMvMD.whcm47&itok=_85zPXJC)
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
![High-Sensitivity Cardiac Troponin ACS](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Athena-%20Poppas_0.png?VersionId=uAw7s0xUwfjE1_1xcLbM7odh7YHQJw7K&itok=pSrlvyyg)
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
![01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-03/Parallax_01_1200x628.jpg?VersionId=8YtGXyCvpISHGUAWuUfXgEArl7M4TInv&itok=fTCIJSke)
![EP 60: The Year 2021 in Review with Dr Sukh Nijjer – Part 1| recent cardiology trials](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/1920x1080_PP_EP60.png?VersionId=5RD29a41Ka6RNtdDgzazifTh_tnmcFut&itok=vkisLegl)
![Parallax AHA Edition: 3 Trials that will change your practice with Dr Amit Khera](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/EP59_PP_1920x1080_Web_Thumbnail.png?VersionId=R.EhdsJ426kSouiUM7QobjhJoBxYBRuk&itok=x73s1klk)
![Parallax TCT Edition: 3 Trials that will Change Your Practice with Prof Mamas Mamas](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/PP_EP58_1920x1080_Web_Thumbnail.png?VersionId=wvsTjPMZ2PhW5QUtl9QIEj6FIS3xwS4A&itok=TzPo3hwm)
![Academic Success, Decision-making & Pragmatic Approach](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/EP57_PP_Social_Artwork2_0.png?VersionId=Z.tlaafPFucKKSQY1g6gOM5MfOLlPqI8&itok=kzt1-DFg)
![Parallax HFSA Edition: Diversity, Equity, Inclusion & Belonging with Dr Nancy M. Albert](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/EP56_PP_Social_Artwork2.png?VersionId=VZ0MM2neqFfUYaGSKTxejSWQQtSYxynC&itok=JfvloKdX)